## Официальные рекомендации

* [Руководства по интерпретации данных последовательности ДНК человека, полученных методами массового параллельного секвенирования (МПСMPS) (редакция 2024, версия 3)](https://docs.google.com/document/d/1_tFCEzjARo3dx3cTWFa-4BPLgOpf8Lh7xYpr2ncp5bw) - 2024г. - проект, есть картинка с алгоритмом определения класса мутаций.
<br/>[Презентация](https://ngs.med-gen.ru/recommendations/%D0%A0%D0%B5%D0%BA%D0%BE%D0%BC%D0%B5%D0%BD%D0%B4%D0%B0%D1%86%D0%B8%D0%B8%20%D0%BF%D0%BE%20%D0%B8%D0%BD%D1%82%D0%B5%D1%80%D0%BF%D1%80%D0%B5%D1%82%D0%B0%D1%86%D0%B8%D0%B8%20%D0%B4%D0%B0%D0%BD%D0%BD%D1%8B%D1%85%20NGS%202024.pdf)

* [Руководство по интерпретации данных последовательности ДНК человека, полученных методами массового параллельного секвенирования (MPS)(редакция 2018, версия 2)](https://www.medgen-journal.ru/jour/article/view/642/402) - 2018. Оно же на сайте
  
* [Рекомендации для интерпретации данных, полученных методом Next Generation Sequencing (NGS)](https://ngs.med-gen.ru/mgngs16/results/%D0%A0%D0%B5%D0%BA%D0%BE%D0%BC%D0%B5%D0%BD%D0%B4%D0%B0%D1%86%D0%B8%D0%B8%20%D0%B4%D0%BB%D1%8F%20%D0%B8%D0%BD%D1%82%D0%B5%D1%80%D0%BF%D1%80%D0%B5%D1%82%D0%B0%D1%86%D0%B8%D0%B8%20NGS%20%D0%B4%D0%B0%D0%BD%D0%BD%D1%8B%D1%85.pdf) - 2016г. устарело


* [РУКОВОДСТВО по интерпретации клинически значимых нуклеотидных вариантов при солидных опухолях с целью выбора тактики терапии и предоставлению результатов, полученных методом секвенирования следующего
поколения (NGS) ](https://www.cancergenome.ru/materials/NGS.pdf) - 2022?

## ACMG Standards and Guidelines
* [Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology]
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544753/) - 2015
  
* [Sherloc: a comprehensive refinement of the ACMG–AMP variant classification criteria](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632818/) - 2017
  <br/>Sherloc builds on the strong framework of 33 rules established by the ACMG-AMP guidelines and introduces 108 detailed refinements, which support a more consistent and transparent approach to variant classification.

* [Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework](https://pubmed.ncbi.nlm.nih.gov/29300386/) - 2018
  <br/>Only 2 of the 18 existing ACMG/AMP evidence combinations were mathematically inconsistent with the overall framework.

* [Fitting a naturally scaled point system to the ACMG/AMP variant classification guidelines](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011844/) - 2020

* [Clinical Interpretation of Sequence Variants](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431429/)
<br/>Figure - Strategic planning workflow for sequence variant interpretation.

* [Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6185798/)
<br/>PVS1 decision tree.

## Калькулятор патогенности
* [Калькулятор патогенности вариантов нуклеотидной последовательности](http://calc.generesearch.ru/)
<br/>На основе "Руководство по интерпретации данных последовательности ДНК человека, полученных методами массового параллельного секвенирования (MPS)
(редакция 2018, версия 2))

* [vaRHC: an R package for semi-automation of variant classification in hereditary cancer genes according to ACMG/AMP and gene-specific ClinGen guidelines]
(https://pubmed.ncbi.nlm.nih.gov/36916756/) - 2023
<br/>vaRHC has been developed to automate as much as possible the process of variant classification in hereditary cancer. It follows gene-specific guidelines for APC, ATM, CDH1, CHEK2, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN and TP53, and the updated general ACMG/AMP rules for other cancer susceptibility genes. The final classification is obtained according to Tavtigian’s natural scoring Bayesian-based metastructure (Tavtigian et al., 2020) but also considering some of the proposed CanVIG-UK incompatibilities.

* [Cancer SIGVAR: A semiautomated interpretation tool for germline variants of hereditary cancer-related genes](https://pubmed.ncbi.nlm.nih.gov/33565189/)
<br/> [sci-hub](https://sci-hub.ru/10.1002/humu.24177) - 2021

* [InterVar: Clinical interpretation of genetic variants by the 2015 ACMG‐AMP guidelines](https://www.cell.com/ajhg/fulltext/S0002-9297(17)30004-6) - 2017
<br/>https://wintervar.wglab.org/   https://github.com/WGLab/InterVar - последнее обновление 3 года назад
<br/>A bioinformatics software tool for clinical interpretation of genetic variants by the ACMG-AMP 2015 guidelines

* PathoMAN [Toward automation of germline variant curation in clinical cancer genetics](https://www.gimjournal.org/article/S1098-3600(21)05005-X/fulltext) - 2019
<br/>https://pathoman.mskcc.org/

* [ClinGen Pathogenicity Calculator: a configurable system for assessing pathogenicity of genetic variants](https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-016-0391-z) - 2017
  <br/>https://calculator.clinicalgenome.org/site/cg-calculator

## Список полезных ресурсов
https://docs.google.com/spreadsheets/d/10n7FXcRmZ4l2SnFfTTGaLp_JvkuE14-7q2PV49TY7os/
